Abbvie Stock News

Don''t worry about Humira''s impending loss of exclusivity in the U.S.

Abbvie Inc (ABBV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $255B. The stock is currently up 8.0% year-to-date, up 45.1% over the past 12 months, and up 195.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.2%, and the S&P 500 fell 1.1%. Trading Activity Trading volume this week was 10.8% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -293.5% The company's stock price performance over the past 12 months beats the peer average by 404.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 4.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Is now an optimal time to buy?

Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. The stock is currently up 6.7% year-to-date, up 43.3% over the past 12 months, and up 195.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Trading Activity Trading volume this week was 13.6% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -220.6% The company's stock price performance over the past 12 months beats the peer average by 496.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 5.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

We''re trimming AbbVie on Tuesday, with shares up to a new all-time high. We also see news on Boeing as "priced in" already.

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Shares of AbbVie Inc. (NYSE: ABBV ) traded at a new 12-month high today of $145.46. This new high was reached on below average trading volume as 1.8 million shares traded hands, while the average 30-day volume is approximately 8.4 million shares. Based on a current price of $144.81, AbbVie Inc. is currently 1.1% above its average consensus analyst price target of $143.19. AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs … Full story available on Benzinga.com

Berkshire Bought Activision In Q4 Ahead Of Microsoft Purchase; Added To Chevron, Trimmed Visa, Mastercard And Pharma Stocks In the weeks before Microsoft made the surprise announcement it was acquiring the troubled Activision, the market was rife with speculation that Berkshire itself could make a play - no pun intended - for the foundering video game company whose stock had tumbled so much in the fourth quarter amid poor earnings and sexual harassment scandals, many viewed it as a deep value play suitable even for Warren Buffett. In retrospect, that didn''t pan out, but as we learned today after the quarterly 13F bonanza hit, Berkshire was buying Activision in Q4 when the stock was tumbling, and as of Dec 31, Berkshire owned 14.658 million shares of Activision stock, representing 1.9% of the shares outstanding. Assuming Buffett bought around the average price for the quarter, or $65, Berkshire made around $250 million on that purchase alone which is not a bad payout for a few weeks worth of work (one wonders if the information that Buffett was buying somehow leaked, and prompted Microsoft''s unexpected acquisition of ATVI).

The conglomerate also adds to its Chevron holding, while cutting back on Bristol Myers Squibb and AbbVie.

Warren Buffett''s Berkshire Hathaway Inc said on Monday it added nearly 14.7 million shares of video game maker Activision Blizzard Inc ahead of Microsoft Corp''s $68.7 billion deal to buy the company. The company also added to its position in energy giant Chevron Corp while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc during the quarter that ended in December. The changes were disclosed in a regulatory filing detailing Berkshire''s U.S.-listed holdings at the end of the year.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sea Ltd, AbbVie, Toronto Dominion Bank and Avis Budget were our top stock trades for Tuesday. Here''s how the charts look now. The post 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First…

Abbvie Inc (ABBV) shares closed today at 1.7% below its 52 week high of $144.42, giving the company a market cap of $252B. The stock is currently up 6.5% year-to-date, up 43.5% over the past 12 months, and up 197.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 17.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -227.2% The company's stock price performance over the past 12 months beats the peer average by 398.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 34.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $143.98, giving the company a market cap of $253B. The stock is currently up 6.9% year-to-date, up 42.2% over the past 12 months, and up 196.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.0%. Trading Activity Trading volume this week was 32.2% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -279.2% The company's stock price performance over the past 12 months beats the peer average by 302.6% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 35.5% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Privately held Healis Therapeutics acquired a key botulinum toxin patent from AbbVie (ABBV)

AbbVie (ABBV) said it reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Venclexta (venetoclax) in combination with azacitidine to treat patients with